YPrime Unveils a Transformative Brand Focused on Solving for Certainty in Clinical Trials
22 janv. 2024 07h45 HE
|
Y-Prime, LLC
YPrime announces bold rebranding and re-commitment to provide cutting-edge technologies to streamline and accelerate clinical trials.
OBI-992 獲FDA核准展開一/二期臨床試驗
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2為標靶、自行研發的抗體藥物複合體(ADC)新藥OBI-992,已獲美國食品藥物管理局(FDA)核准一/二期臨床試驗申請,以評估其安全性及療效。 ...
OBI-992 获FDA核准展开一/二期临床试验
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174.TWO)今(3)日宣布,旗下以TROP2为标靶、自行研发的抗体药物复合体(ADC)新药OBI-992,已获美国食品药物管理局(FDA)核准一/二期临床试验申请,以评估其安全性及疗效。 ...
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
02 janv. 2024 08h00 HE
|
Sterling Infosystems, Inc
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
19 déc. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
04 déc. 2023 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
20 nov. 2023 04h00 HE
|
AKAMPION
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria JERUSALEM, Israel, November 20,...
Medical Devices Testing Services Market Size Worth USD 22.43 Billion in 2032 | Emergen Research
15 nov. 2023 12h24 HE
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Medical Devices Testing Services Market will be worth USD 22.43 Billion by 2032, according to a current analysis by Emergen Research. The...
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
13 nov. 2023 02h00 HE
|
Blueberry Therapeutics
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...